evolution of facial aesthetic treatment over 5 or more years: an international, retrospective,...

P8294Evaluation of safflower oil on cellulitis and localized fat

Samanta Nunes, MD, Samanta, S~ao Paulo, Brazil

Safflower oil is full of unsaturated fatty acids, such as omega-9 and omega-3, andplays an important role in lipid metabolism. It has been shown that it can decreasecholesterol levels. The objective of this study is to evaluate its potential effect oncellulitis and localized fat. Twenty-two women were evaluated on 0, 30, 60, and 90days regarding Body Mass Index (BMI), tights circumferences, photographic images,and degree of cellulitis (NurnbergereMuller). Patients were instructed to maintainregular dietary habits and physical activity, and no medication or procedure weredone during the treatment. They received 1.6 g of omega-9 (oleic acid) and 9 g ofomega-3 (linoleic acid). Results showed a reduction of the BMI between 0.1-0.9kg/m2, weight losses between 0.5-3.2 kg after 90 days, and also a reduction on tightscircumferences of 0.3 to 8.8 cm after 90 days. Improvement of the degree ofcellulitis was also observed. The conclusion is that this study may show a positiveeffect of the safflower oil on treating localized fat and cellulitis. More studies are stillrequired to validate this beneficial activity.

MAY 201

oil was provided by FQM.

P8314Evolution of facial aesthetic treatment over 5 or more years: An interna-tional, retrospective, cross-sectional analysis of continuous onabotuli-numtoxin A treatment

Alastair Carruthers, MD, Carruthers Clinical Research, Vancouver, BritishColumbia, Canada; Conor Gallagher, PhD, Allergan, Inc, Irvine, CA, UnitedStates; Sarah Darmody, Allergan, Inc, Irvine, CA, United States

Objective: Assess the evolution of facial aesthetic treatment in patients receivinglong-term continuous treatment with onabotulinumtoxin A.

Study Design: This international, retrospective chart review included patients aged¼ 18 years at the time of their first onabotulinumtoxin A aesthetic treatment and ahistory of¼ 5 years of continuous onabotulinumtoxinA treatments (yearly average¼2 treatments, including 1 glabellar lines [GL] treatment/year for ¼ 5 years). Medicalrecords were reviewed for facial areas treated with onabotulinumtoxin A, number oftreatments, dosage per facial treatment area, concomitant facial aesthetic pro-cedures and treatments, and onabotulinumtoxin Aerelated adverse events (AEs),thus providing extensive data on the progression of patients’ aesthetic treatmentsand clinical trends during the period of widespread adoption of injectable aesthetictreatments.

Results: Of 207 patients included, 194 met criteria for the per-protocol analysis.Patients were treated with onabotulinumtoxinA for amean of 9.16 2.9 years (range,5.0-16.8) and data were collected from 5112 treatments, of which 4402 were GLtreatments. Mean age at first injection was 46.3 6 9.9 years. The longer patientswere treated, the younger they perceived themselves to look. GL treatmenttemporally preceded crow’s feet lines (CFL), followed closely by forehead lines(FHL). Dosing in GL and CFL remained relatively stable over the period 1999 to 2012,although FHL dose decreased. A majority of patients (85%; 165/194) receivedtreatment with fillers, of which 111 began, on average, 38 months after firstonabotulinumtoxinA treatment. The remainder received fillers previously (n ¼ 25)or began in the same year (n ¼ 29). In addition to a cumulative increase inonabotulinumtoxin A treatments in GL, FHL, and CFL over time, there wereincreases in facial aesthetic treatments with injectable fillers, energy-based devices,and prescription topical creams. AEs were infrequent, mostly mild in severity, anddeclined markedly over the first year of treatment.

Conclusions: This study shows that continuous onabotulinumtoxin A treatmentsover several years are safe and can be used in conjunction with other aesthetictreatments. Patients receiving continuous onabotulinumtoxin A treatmentperceived themselves to look younger than their actual age.

Co-authors: N. Sadick, F. Brandt, A.R. Trindade de Almeida, S. Fagien, G. Goodman,H. Raspaldo, K. Smith

d by Allergan.

4

P7803Extract from Cryptomphalus aspersa eggs significantly promotes skinhomeostasis and migration and survival of skin cells in vitro

Salvador Gonzalez, Dermatology Service, Memorial Sloan-Kettering CancerCenter, New York, NY, United States; Angeles Juarranz, Biology Department,Universidad Autonoma de Madrid, Tres Cantos, Madrid, Spain; Eduardo Reyes,Universidad de Alcal�a, Alcal�a de Henares, Madrid, Spain; Maria Matabuena,InnCells, Tres Cantos, Madrid, Spain; S. Lucena, Biology Department,Universidad Autonoma de Madrid, Madrid, Spain

Background: Regenerative properties of skin decrease with age and the search forsubstances that minimize cutaneous aging has been steadily increasing. A patentednatural extract from Cryptomphalus aspersa eggs has been developed whichcarries out regenerative activities when applied topically.

Objectives: To study the in vitro effects of the C aspersa egg extract on skinhomeostasis and cell migration, as well as on cell-cell (E-cadherin, -catenin) and cell-substrate (vinculin, 1-integrin) adhesion protein expression. Moreover, its effects oncell survival and matrix metalloproteinases regulation were also explored.

Methods: Human keratinocyte cell line (HaCaT cells) and primary dermal fibroblasts(HF) were used. To test cell proliferation, colorimetric MTT assay was performed.Cell migration was studued using wound-healing assays complemented with MTTassays to avoid subjectivity in result quantification, whereas Western blot andimmunofluorescence microscopy were carried out to test the expression ofdifferent cell adhesion proteins. ELISA and immunofluorescence were performedto determine fibronectin, MMPs and collagen 1.

Results: C aspersa egg extract clearly promotes proliferation and migration ofHaCaT cells in a time and dose-dependent manner facilitating tissue homeostasis.Moreover, treatment with C aspersa egg extract increases the migratory behaviorand the expression of adhesion molecules in both HaCaT and HF. Finally, C aspersaegg extract also improves cell survival and promotes phosphorylation of FAK andnuclear localization of beta-catenin.

Conclusion: C aspersa egg extract promotes regeneration of epithelial tissue, beingmore effective on fibroblasts than keratinocytes. The dermal effect seems supportedby significantly increasing collagen synthesis and fibronectin production. Moreover,MMPs release is downregulated in both types of cutaneous cells. All these effectssuggest a potential clinical impact in skin rejuvenation and regeneration of woundedtissues.

d by Industrial farmaceutica Cantabria SA (IFC SA).

P8367Fractional erbium 2940-nm laser and acoustic pressure wave ultrasoundmodule for transepidermal delivery of cosmetic antiaging ingredients forwrinkles and pigment changes: A randomized, split face side by side study

Stefanie Luebberding, MS, Dermatology and Laser Surgery Center, New York, NY,United States; Macrene Alexiades-Armenakas, MD, PhD, Dermatology and LaserSurgery Center, New York, NY, United States

Skin aging is a complex multifactorial process that comes along with the agingprocess of the human body resulting in the development of facial wrinkles andpigment changes on the skin surface. Numerous treatments, such as ablative orfactional laser therapy, or the use of cosmeceuticals have been used to treat theseskin aging signs. Recently, a device which combines two technologies has beeninvented using a fractional ablative Er:YAG 2940-nm laser, creating micro channelsfor transepidermal delivery (TED) of cosmeceuticals, in combination with anacoustic pressure wave ultrasound (Impact) module for enhancing the penetrationof the cosmetic formulation beyond the dermoepidermal junction into the deep skintissue. The aim of this study was to evaluate the safety and efficacy of fractionalablative Er:YAG 2940-nm laser combined with cosmeceuticals and impact technol-ogy in the treatment of wrinkle, and pigmented skin. Fourteen subjects wereincluded in this single site, open label study. The subjects were assigned to 2 splitface side by side treatments (21 6 2 days) and additional 1- and 3-month follow-upvisits. According to randomization, one side of the face was treated with thefractional Er:YAG laser plus cosmetic formulations, while the other side was treatedwith the fractional Er:YAG laser plus cosmetic formulations plus the Impact module.Photographs were taken and reflectance spectroscopy was performed at baseline,prior to each treatment and during each follow-up visit. Before the initiation of thefirst treatment each subject underwent clinical evaluation. All subjects completedthe trial. Themajority reported no or mild discomfort during treatment. Besides mildto moderate erythema and edema right after the treatment, no severe adverse eventswere observed during the study. Efficacywas assessed by Glogau Photodamage Scaleand GAIS evaluation. The evaluation demonstrated a reduction in wrinkle severityfrom 3.25 to 2.6 and an improvement of the overall assessment. The TED concept of2 technologies in combination—the fractional ablative Er:YAG 2940-nm laser forperforation of the skin creating a passage for cosmecuticals delivery and impactultrasound module for cosmeceuticals enhancement—constitute a solution forovercoming both barriers of stratum corneum and intercellular fluid in cosmeceut-icals delivery into the deep skin tissues for multiple aging skin imperfections. Thetreatment seems to be tolerable, safe, and effective.

d by Alma Lasers.

J AM ACAD DERMATOL AB17